Concepedia

Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials

Sonali M. Smith, Sonali M. Smith, Brandelyn N. Pitcher, Sin‐Ho Jung, Nancy L. Bartlett, Nina D. Wagner‐Johnston, Steven Park, Kristy L. Richards, Amanda F. Cashen, Anthony J. Jaslowski,

The Lancet Haematology · 2017 · 79 citations · 20 references

DOIFull text

Open access

Concepts

References

20

Revised Response Criteria for Malignant Lymphoma

Bruce D. Cheson, Beate Pfistner, Malik E. Juweid et al. · Journal of Clinical Oncology · 2007 · 4.4K citations · Full text

, , +15

Current concepts in the diagnosis and management of cytokine release syndrome

Daniel W. Lee, Rebecca Gardner, David Porter et al. · Blood · 2014 · 2.8K citations

, , +14

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text

, , +14

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Ajay K. Gopal, Brad S. Kahl, Sven de Vos et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

, , +17

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

Khaled Ali, Dalya R. Soond, Roberto Piñeiro et al. · Nature · 2014 · 543 citations · Full text

, , +10